Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Large-Cell, Immunoblastic
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Large-Cell, Immunoblastic
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Large-Cell, Immunoblastic
Description
Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan. MeSH
Hierarchy View
Phase 2 Indicated Drugs (98)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
anti-cd19/20-car vector-transduced t cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cd19/cd22 chimeric antigen receptor t-cells
axicabtagene ciloleucel (Yescarta)
p.dom-wt1-37 dna vaccine and p.dom-wt1-126 dna vaccine
Phase 1 Indicated Drugs (67)
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
bcl-2 antisense oligonucleotide
Other Experimental Indicated Drugs (16)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (23)
Organization Involved with Phase 1 Indications (16)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
